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Background: Cryptococcal antigen (CrAg) screening in individuals 
with advanced HIV reduces cryptococcal meningitis (CM) cases and 
deaths. The World Health Organization recently recommended 
increasing screening thresholds from CD4 ≤100 cells/µL to ≤200 
cells/µL. CrAg screening at CD4 ≤100 cells/µL is cost-effective; 
however, the cost-effectiveness of screening patients with CD4 
101‒200 cells/µL requires evaluation. 
Methods: Using a decision analytic model with Botswana-specific cost 
and clinical estimates, we evaluated CrAg screening and treatment 
among individuals with CD4 counts of 101–200 cells/µL. We estimated 
the number of CM cases and deaths nationally and treatment costs 
without screening. For screening we modeled the number of CrAg 
tests performed, number of CrAg-positive patients identified, 
proportion started on pre-emptive fluconazole, CM cases and deaths. 
Screening and treatment costs were estimated and cost per death 
averted or disability-adjusted life year (DALY) saved compared with no 
screening. 
Results: Without screening, we estimated 142 CM cases and 85 
deaths annually among individuals with CD4 101–200 cells/µL, with 
treatment costs of $368,982. With CrAg screening, an estimated 
33,036 CrAg tests are performed, and 48 deaths avoided (1,017 DALYs 
saved).  While CrAg screening costs an additional $155,601, overall 
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treatment costs fall by $39,600 (preemptive and hospital-based CM 
treatment), yielding a net increase of $116,001. Compared to no 
screening, high coverage of CrAg screening and pre-emptive 
treatment for CrAg-positive individuals in this population avoids one 
death for $2440 and $114 per DALY saved. In sensitivity analyses 
assuming a higher proportion of antiretroviral therapy (ART)-naïve 
patients (75% versus 15%), cost per death averted was $1472; $69 per 
DALY saved. 
Conclusions: CrAg screening for individuals with CD4 101–200 cells/µL 
was estimated to have a modest impact, involve additional costs, and 
be less cost-effective than screening populations with CD4 counts 
≤100 cells/µL. Additional CrAg screening costs must be considered 
against other health system priorities.
Keywords 
Cryptococcal antigen, CrAg, fluconazole, pre-emptive treatment, 
cryptococcal meningitis, HIV, AIDS, cost-effectiveness, modelling, 
Botswana
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Introduction
The 2018 World Health Organization (WHO) guidelines con-
ditionally recommended increasing the CD4 count threshold 
for cryptococcal antigen (CrAg) screening and targeted flu-
conazole treatment from ≤100 cells/µL to ≤200 cells/µL for 
the prevention of cryptococcal meningitis (CM)1. Patients 
with CD4 counts of 101–200 cells/µL are also relatively 
immunocompromised and at risk for CM2, but prevalence of 
CrAg positivity in this population, estimated at 2.0% (95% con-
fidence interval (CI): 1.2-2.7%; 21 studies)3 is substantially 
lower than prevalence among patients with CD4 ≤100 cells/µL. 
The impact and cost-effectiveness of increasing the CrAg 
screening CD4 count threshold have not been systemati-
cally evaluated, and a better understanding of the potential 
impact (in terms of CM cases and deaths avoided), screening 
program resource needs, and cost effectiveness will inform 
countries as they consider changes to national screening 
guidelines.
Botswana had a 2018 estimated adult HIV prevalence of just 
over 20%, with approximately 350,000 adults currently living 
with HIV4. Reflex CrAg screening was adopted in national HIV 
guidelines in 20165. Screening is currently reflexively performed 
in blood samples sent for CD4 testing and found to have a 
CD4 ≤100 cells/µL at the Botswana-Harvard HIV Reference 
Laboratory, which performs most CD4 testing for the greater 
Gaborone region. We previously published a cost-effectiveness 
analysis of CrAg screening at a CD4 threshold of ≤100 cells/µL 
in Botswana. Screening in this population was highly cost-
effective (either cost-neutral or cost-saving across different 
model assumptions) and prevented a significant proportion of 
CM cases and deaths6.
Using data and estimates from Botswana in patients with a 
CD4 count of 101–200 cells/µL, the objective of this analysis 
is to expand our CrAg screening models to include those with 
a CD4 count of 101–200 cells/µL, with an aim of informing 
policy regarding CrAg screening for patients with higher CD4 
counts. As in our previous analysis6, we evaluated CrAg screen-
ing among patients who are antiretroviral therapy (ART)-naïve 
(those targeted for pre-emptive treatment in guidelines) as 
well as ART-experienced patients found to be CrAg-positive 
through reflex CrAg screening. This ART-experienced 
population re-engaging in care and treatment now makes up 
about half of those with incident CM7–9 in the region and are 
likely to derive clinical benefit from pre-emptive fluconazole 
treatment for the prevention of CM.
Methods
Overview
We used a decision analytic model to evaluate the number of 
patients receiving CD4 testing in Botswana who are at risk 
of cryptococcal meningitis and (1) develop CM without CrAg 
screening and (2) with national reflex CrAg screening adop-
tion, as previously described6, but in this analysis focused on 
those with a CD4 count of 101–200 cells/µL. Briefly, CD4 count 
distribution data were obtained from the Botswana-Harvard 
HIV Reference Laboratory10, and local CrAg prevalence and 
titre data used to predict risk for progression to CM in the 
CD4 101–200 cells/µL population. Local data were obtained 
from a 2018–2019 CrAg screening cohort of patients with 
advanced HIV disease in Gaborone, which included over 
900 patients with a CD4 count of 101–200 cells/µL who received 
reflex CrAg screening and were followed for up to 6 months 
for incident CM and mortality11. In our model, based on local 
estimates we assume that 650,000 CD4 tests are performed 
annually for the adult HIV-positive population of 350,000 
(around two tests per patient)10.
Screening module
The screening module (see Figure S1 in extended data12), 
adapted from our previous model6, estimates the proportion of 
patients who receive CD4 testing with a CD4 101–200 cells/µL, 
how many of these patients receive reflex CrAg screening, the 
proportion who are CrAg-positive, and the proportion previ-
ously initiated on ART, i.e. “ART-experienced” (see Figure S1 
in extended data and key parameter assumptions in Table 1). 
From country data10, 5.35% of all CD4 tests performed in 
greater Gaborone have a CD4 T-cell count between 101 and 200 
cells/µL (Table 1). Only a small proportion (15%) of patients 
with a CD4 101–200 cells/µL were ART-naïve in 2018–2019. 
Patients were considered ART-experienced if they had a 
prior history of HIV viral load testing documented in the 
national electronic medical record, as viral load testing is 
exclusively performed after initiation of ART as per national 
guidelines5. In the absence of prior documented viral load testing, 
a patient was assumed to be ART-naïve.
Based on data from the prospective 2018–2019 CrAg screen-
ing cohort11, among screened outpatients in the 101–200 cells/µL 
CD4 T-cell count range, CrAg prevalence was estimated at 
3.1%, 35% of whom had a history of treated CM; thus 2.0% of 
screened outpatients with a CD4 count of 101–200 cells/µL 
are estimated to be incident CrAg positives (no history of prior 
CM) and the target population for pre-emptive fluconazole 
treatment. 
We used serum CrAg titre data to stratify the risk of CrAg- 
positive patients progressing to CM13, with a titre >1:160 cor-
responding with a high risk for incident cryptococcal disease. 
Approximately 20% of CrAg-positive outpatients with a CD4 
101–200 cells/µL had a high CrAg titre, compared to 59% 
among those with lower CD4 counts of ≤100 cells/µL6. For our 
CD4 101–200 cells/µL models, we assume that patients who 
screen CrAg-positive and return to clinic are started on pre-
emptive fluconazole therapy and none receive a diagnostic 
lumbar puncture to evaluate for central nervous system infec-
tion, given the lower distribution of CrAg titres in the CD4 
101–200 cells/µL population compared to ≤100 cells/µL and 
frequent lumbar puncture refusal in routine-care settings14.
Our base model assumes that 5% of patients with CD4 
101–200 cells/µL do not receive CrAg screening due to labora-
tory error or assay stockout and that 10% of patients who screen 
CrAg-positive do not return to clinic to begin pre-emptive flu-
conazole, putting them at higher risk for progression to CM. 
Given the comparatively lower CrAg titre distribution in 
patients with higher CD4 counts, we expect a longer delay until 
progression to CM in the absence of pre-emptive fluconazole 
meaning that fewer patients who delay returning for follow-up 
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appointments would be expected to develop early CM in this 
group than among those with CD4 cell counts ≤100 cells/µL 
(Figure S1 in extended data12).
Base model: CrAg screening at CD4 101–200 cells/µL, 
treatment for both ART-naïve and ART-experienced
The base model treatment module (see Figure S2 in extended 
data12 and key parameter assumptions in Table 1) includes 
outcomes for patients (1) with a CD4 count of 101–200 
cells/µL who do not receive CrAg screening, (2) who are 
screened and CrAg-positive but do not receive follow-up to 
initiate pre-emptive therapy, and (3) who are screened and started 
on pre-emptive fluconazole therapy.
Full modeling assumptions are detailed in a Microsoft Excel 
file accessible online12. Risk of progression to CM is dic-
tated by whether a patient has a high- (>1:160) or low (≤1:160) 
CrAg titre13. Outcomes of patients who develop incident CM 
are informed by local mortality data from Botswana, with 
approximately 50% of patients dying within 10 weeks of 
CM diagnosis under routine care conditions8,16. Patients who 
are recognized as CrAg-positive and started on pre-emptive 
fluconazole but subsequent fail therapy and are admitted to 
the hospital for the management of CM are assumed to have 
better clinical outcomes (25% versus 50% 10-week mortal-
ity) based on limited data from South Africa13. Some patients 
who develop CM and survive hospitalization may develop 
relapsed CM. Given the small proportion of these patients and 
small clinical and public health impact, we do not consider them 
further in our models.
With reflex CrAg screening, patients receive CrAg screen-
ing based on CD4 count regardless of prior ART status. How-
ever, most (85%) patients with a CD4 count of 101–200 cells/µL 
Table 1. Key parameters, estimates, and sources of data for base model.
Screening Module
Parameter CD4 101–200 cells/µl Source(s)
% within CD4 strata 5.35% BHHRL data
CrAg prevalence within CD4 strata (outpatient), % 3.1% 3,11
Among CrAg-positive individuals:
Proportion with prior CM, % 35% 11
Proportion with CrAg titre ≥1:160, % 20% 11
Proportion ART-naïve, % 15% 11
Return to clinic for pre-emptive treatment, % 90% Assumption
Treatment Module
Parameter CD4 101–200 cells/µl Source(s)
Hospitalized if missed CrAg+ and develops CM, % 80% Assumption
10-week CM mortality 50% 8
CM relapse 17% 8
Fail pre-emptive therapy (if receive fluconazole) 
- High CrAg titre, ART-naive* 20% 13,15
Fail pre-emptive therapy (if receive fluconazole) 
- Low CrAg titre ART-naive* 5% 13,15
Hospitalized if fail pre-emptive therapy and 
develop CM 90% Assumption
10-week mortality 25% 13
CM relapse 17% 8
Hospitalized if diagnosed with CM at urgent 
follow-up visit 100% Assumption
10-week mortality 25% 13
CM relapse 17% 8
ART = antiretroviral therapy; BHHRL = Botswana-Harvard HIV Reference Laboratory; CrAg = 
cryptococcal antigen; CM = cryptococcal meningitis
* Assumptions about failed pre-emptive therapy for ART-experienced as included in extended data and 
underlying data12
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are now ART-experienced according to recent cohort data from 
Botswana 2018–201911. Very little outcome data exist in 
this disparate sub-population, which consists of patients: 
(1) recently started on ART; (2) ART-experienced who 
defaulted and are now re-establishing care; and (3) ART- 
experienced but with treatment failure. From local 2018–2019 
cohort data in Botswana, approximately 75% of these ART-
experienced patients are considered to have recently started on 
ART (with an undetectable HIV viral load in the previous three 
months), 20% are on ART but with a recent unsuppressed HIV 
viral load signifying treatment failure, and 5% have a history of 
recent ART use without a recent HIV viral load signifying likely 
ART default17. For those recently started on ART, we assumed 
a 33% reduction in risk of CM for those with CD4 101–200 
cells/µL compared to our previous estimates for those with 
CD4 ≤100 cells/µL. In our base model, based on prospec-
tive cohort data14, those recently started on ART with a sup-
pressed HIV viral load have a low risk of progression to CM 
without pre-emptive fluconazole therapy (7%), with a greater 
risk in those with ART treatment failure (60%) and ART 
defaulters (33%). The combined risk of progression to CM 
for all ART-experienced patients in the CD4 101–200 cells/µL 
group is assumed to be 19% without pre-emptive treatment. 
We estimate an 87.5% reduction in risk of incident CM with 
pre-emptive fluconazole (factoring in a relatively low baseline 
CrAg titre distribution in this group)18.
CrAg screening and treatment unit costs
Costing data for CrAg screening, pre-emptive therapy, and 
CM treatment costs are derived using local costing data 
when available (Table 2 and underlying data12)6. Patients who 
screen CrAg-positive and receive pre-emptive fluconazole are 
treated with fluconazole 1200 mg/day for 2 weeks, followed 
by 800 mg/day for 8 weeks, then 200 mg/day maintenance 
fluconazole for an average duration of six months pending CD4 
count recovery. For patients who progress to CM, hospital 
bed-day costs, factoring length of hospital admission8, were 
derived using WHO-CHOICE estimates19–21. CM treatment costs 
are based on two inpatient weeks of amphotericin B deoxycho-
late with high-dose fluconazole, intravenous fluid and electrolyte 
Table 2. Included cost estimates for CrAg screening and pre-emptive 
treatment and for cryptococcal meningitis treatment.
CrAg screening and pre-emptive therapy *
Parameter Estimate (USD) Source(s)
CrAg LFA $4.71 IMMY wholesale plus 
additional costs
Pre-emptive fluconazole 
1200 mg/day x2 weeks 
800 mg/day x8 weeks 
200 mg/day x26 weeks
$0.51 / 200 mg tablet 
x 490 tablets = $247.54
CMS; proportion with 
treatment failure or 
partial adherence
Extra visit $9.43 Assumption
Treatment Module *
Parameter Estimate (%) Source(s)
Hotel costs  
                           17-day hospital stay
$188.51 / hospital day 8,17
Hospital drug and procedure costs 
    Including 14 days AmBd and FLU, 





      FLU consolidation/maintenance,  
                                    Extra clinic visit 
$226.37 CMS
Laboratory costs 
                             2 FBC, 4 U/E, 1 ALT
$71.00 BHHRL; WHO 
guideline1
* Underlying data includes detailed costing estimates 12
ALT = alanine aminotransferase; AmBd = amphotericin B deoxycholate; BHHRL = Botswana 
Harvard HIV Reference Laboratory; CM = cryptococcal meningitis; CMS = Central Medical 
Stores; FBC = full blood count; FLU = fluconazole; KCl = potassium choloride; Mg = magnesium 
supplementation; NS = normal saline; U/E = urea and electrolyte testing; WHO = World Health 
Organization
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supplementation, and laboratory monitoring, followed by con-
solidation and maintenance fluconazole, as recommended 
in national treatment guidelines5.
Outcomes
Our model estimates the number of CM cases and CM-
related deaths nationally in the population with a CD4 
101–200 cells/µL without CrAg-screening and pre-emptive 
fluconazole therapy along with treatment costs for CM man-
agement. With implementation of CrAg screening, we then 
model the number of CM cases and CM-related deaths pre-
vented in the base model (with pre-emptive fluconazole for all 
CrAg-positive patients) along with associated costs for screen-
ing, pre-emptive fluconazole therapy, and CM treatment. We esti-
mate the cost per death averted and cost per disability-adjusted 
life year (DALY) saved compared to no screening, assum-
ing an average age of death of 36 years8. With a 3% annual 
discount rate and age-specific life expectancy from WHO 
Global Health Observatory, 21.4 DALYs are saved per avoided 
death6,22. 
Sensitivity analyses
Three main sensitivity analyses are reported to account for 
key areas of parameter uncertainty. The complete Excel-based 
model is provided as underlying data12 so that alternative 
sensitivity analyses can be completed by interested readers.
Sensitivity analysis 1 (SA1): In this analysis, we assume 
that in some real world settings a lower proportion of 
CrAg-positive patients are started on pre-emptive fluconazole 
after laboratory testing (50% versus 90% in the base model) 
because of programmatic barriers such as inadequate commu-
nication of test results to clinics, a lack of fluconazole avail-
ability in clinics, lack of provider awareness of treatment 
guidelines, or for other reasons. This analysis still assumes 
that 90% of patients attended in outpatient clinics and receiving 
CD4 testing will stay engaged in health care. Other parameters 
remain the same as the base model.
Sensitivity analysis 2 (SA2): In this model, we assume less 
benefit of pre-emptive fluconazole in CrAg-positive patients, 
with a 75% rather than 87.5% reduction in incident CM. 
This is to account for significant uncertainty in the benefits of 
pre-emptive fluconazole in this population with a higher CD4 
count, and for possible sub-optimal adherence to therapy. 
Other parameters remain the same as the base model.
Sensitivity analysis 3 (SA3): In this model, we test our param-
eters with a higher proportion of ART-naïve patients receiv-
ing CD4 testing and CrAg screening (75% versus 15% in the 
base model). Other parameters remain the same as the base 
model. This is to provide estimates applicable to settings with 
less mature ART programmes where a higher proportion of indi-
viduals with CD4 counts of 101–200 cells/µL are likely to be 
ART-naïve.
Results
Cryptococcal meningitis cases and costs without 
screening
Without CrAg screening (Table 3), we estimate 142 annual 
cases of incident CM in Botswana among those with a CD4 
test result 101–200 cells/µL. Unlike in our prior analysis of 
Table 3. Cryptococcal meningitis outcomes and costs of treatment without CrAg screening.*









Identified for preemptive treatment 
(but did not receive), but did not 
develop CM – survives
0.0 0 0.0 0
Identified for preemptive treatment, 
receives treatment, survives 0.0 0 0.0 0
Not hospitalized, dies 5.8 0 22.5 0
Hospitalized, dies < 10 weeks 11.6 31,870 45.0 123,939
Hospital, survives maintenance 9.6 36,191 37.4 140,742
Hospital, CM relapse 2.0 7,413 7.7 28,827
Total Treatment Costs 75,474 293,508 368,982
Total Screening Costs (reflex policy) 0 0 0
Total Costs 75,474 293,508 368,982
Total Cases of CM 28.9 112.6 142
Total Deaths from CM 17.4 67.5 85
ART = antiretroviral therapy; CrAg = cryptococcal antigen; CM = cryptococcal meningitis
* Models assumes 650,000 CD4 T-cell count tests performed annually in Botswana
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screening in the CD4 ≤100 cells/µL sub-population, most of these 
incident CM cases (113 of 142, 79%) are in ART-experienced 
patients6. Of patients with incident CM, 60% (85/142) are 
estimated to die (including those diagnosed and managed 
in hospital and those who die outside of the hospital with-
out a confirmed diagnosis). The total estimated CM treatment 
costs are $368,982 annually for the health care system.
Base model: CrAg screening at CD4 101–200 cells/µL, 
treatment for both ART-naïve and ART-experienced
With implementation of reflex CrAg screening (Table 4), 
33,036 CrAg tests are performed at a cost of $155,601. Pre-
emptive treatment averted 48 deaths compared to no screening 
(1,017 DALYs saved). While CrAg screening costs an addi-
tional $155,601 compared to no screening, treatment costs 
fall by $39,600 (preemptive treatment plus hospital-based CM 
treatment), for a net increase of $116,001 (Table 5). Com-
pared to no screening, high coverage of CrAg screening and 
pre-emptive treatment for CrAg-positive individuals in this 
population is associated with a cost of $2440 per one death 
averted or $114 per DALY saved (Table 5).
Sensitivity analyses
SA1 and SA2 assume a lower proportion of CrAg positive are 
started on pre-emptive fluconazole and a reduced benefit of pre-
emptive fluconazole therapy for CrAg-positive patients with 
Table 5. Summary of costs and outcomes for no screening and screening plus pre-emptive treatment.









Cost per death 
averted (USD)
Cost per DALY 
saved (USD)
No screening 85 368,982 n/a n/a n/a n/a n/a
Base model: Screening 101–200 
, preemptive treatment to both 
ART-naïve and ART-experienced 37 484,983 116,001 48 1017 2440 114
ART = antiretroviral therapy; CrAg = cryptococcal antigen; CM = cryptococcal meningitis; DALY = disability-adjusted life year
* Models assumes 650,000 CD4 T-cell count tests performed annually in Botswana
Table 4. Outcomes with CrAg screening and pre-emptive fluconazole for ART-naïve and ART-experienced (base 
model).









Identified for preemptive treatment (but did 
not receive), but did not develop CM – survives 6.6 0 41.9 0
Identified for preemptive treatment, receives 
treatment, survives 75.3 19,361 453.3 116,472
Not hospitalized, dies 2.5 28 9.9 46
Hospitalized, dies < 10 weeks 5.1 14,004 20.0 55,142
Hospital, survives maintenance 6.7 25,203 20.6 77,989
Hospital, CM relapse 1.4 5,162 4.2 15,974
Total Treatment Costs 63,759 265,623 329,382
Total Screening Costs (reflex policy) 155,601 0 155,601
Total Costs 219,360 265,623 484,983
Total Cases of CM 15.5 54.7 70
Total Deaths from CM 7.5 29.9 37
ART = antiretroviral therapy; CrAg = cryptococcal antigen; CM = cryptococcal meningitis
* Models assumes 650,000 CD4 T-cell count tests performed annually in Botswana
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a CD4 101–200 cells/µL, respectively, which may be more 
realistic under many routine care conditions. Both models 
will therefore result in a smaller public health benefit to CrAg 
screening and a higher incremental cost per death or DALY 
saved. For SA1, an estimated 25% (21/85) of deaths are averted 
with treatment of both ART-naïve and ART-experienced with 
a cost per death averted of $7476 or $349 per DALY saved 
(Figure 1). For SA2, 52% (44/85) of deaths are averted with 
treatment of ART-naïve and experienced at a cost per death 
averted of $3360 or $157 per DALY saved. For SA3, assum-
ing a higher proportion of ART-naïve patients are among the 
screened population (75% versus 15%) results in slightly 
enhanced public health benefit and cost per death or DALY 
saved as the base model (see Excel file with underlying 
data12), with an estimated 56% (60/107) reduction in 
CM-related deaths at a cost of $1472 per death averted and 
$69 per DALY saved. Overall estimated costs, number of CM 
cases, number of deaths averted, and DALYs saved for the 
base model and sensitivity analyses are summarized in Figure 2. 
Discussion
We used local data from Botswana to estimate the cost and impact 
of laboratory-based CrAg screening for HIV-positive patients 
with CD4 counts 101–200 cells/µL across a range of assump-
tions. Compared to screening in patients with very advanced 
HIV disease (CD4 ≤100)6, the benefit of screening for those 
with higher CD4 counts, in terms of avoided CM cases and 
deaths, is less marked. Under base model assumptions com-
pared to no screening for this higher CD4 category of patients, 
Figure 1. Estimated costs per death averted and disability-adjusted life year saved under base model and sensitivity analyses. 
DALY = disability-adjusted life year; SA = sensitivity analysis; USD = United States dollar.
48 deaths are averted and screening costs of about $156,000 
are offset by a $40,000 reduction in treatment costs (mainly 
CM-based hospital care and treatment). The cost per death 
averted through CrAg screening and pre-emptive fluconazole 
therapy was estimated at about $2400 ($114 per DALY avoided). 
If substantially fewer patients who screen CrAg-positive are 
started on pre-emptive fluconazole therapy (50% compared 
to 90% in the base case analysis), which might better reflect 
some real-world conditions without focused efforts on provid-
ing preemptive treatment, the estimated cost per death averted 
increases to over $7000 (and $349 per DALY saved).
Compared to prior analyses of CrAg screening for patients 
with CD4 ≤100 cells/µL, fewer CrAg positive patients with 
CD4 101–200 cells/µL are likely to have high CrAg titres 
(~20% in the higher CD4 group compared to ~60% in the 
lower CD4 group11,14), which reduces the risk of incident 
CM and failure of pre-emptive fluconazole13. In addition, over-
all CrAg prevalence among the CD4 101–200 cells/µL group 
is estimated to be less than the CD4 ≤100 cells/µL group. 
Both of these factors reduce the benefit of screening among 
patients with higher CD4 counts. 
As of 2021, Botswana has an advanced ART program. 
Whereas CrAg screening guidelines have primarily focused on 
ART-naïve patients1, a large majority of patients with advanced 
HIV disease in Botswana are ART-experienced. From recent 
data of 2018–2019, we found that most outpatients receiving 
CD4 testing in the greater Gaborone region with a CD4 count 
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Figure 2. Summary of total estimated programmatic costs, number of cryptococcal meningitis cases, cost per deaths averted, 
and cost per disability-adjusted life year saved under base model and sensitivity analyses. ART = antiretroviral therapy; CM = 
cryptococcal meningitis; CrAg = cryptococcal antigen; DALY = disability-adjusted life year.
of 101–200 cells/µL were currently on ART11. We included 
a sensitivity analysis assuming that a majority (75%) of 
patients who received CD4 testing and CrAg screening were 
ART-naïve, which may inform other health systems with a 
higher proportion of ART-naïve patients receiving CrAg screen-
ing with ART initiation. This sensitivity analysis showed a 
slightly better impact and cost-effectiveness compared to the 
base model assuming most patients were ART-experienced 
although screening was still not cost-neutral or cost-saving.
This study is subject to a number of limitations. First, we 
used local clinical and costing estimates. The relative costs 
of CrAg screening, pre-emptive fluconazole therapy, and 
CM treatment between different health systems may impact 
cost-effectiveness of CrAg screening between settings. Secondly, 
the base model presents optimistic management assump-
tions, with about 90% of CrAg-positive patients started on 
pre-emptive therapy and a nearly 90% reduction in incident 
CM assuming relatively good adherence. Sensitivity analyses 
showed that under less ideal assumptions the cost per death 
averted or DALY saved could increase substantially. Nota-
bly, under no model assumptions was CrAg screening in this 
population estimated to be cost-neutral or cost-saving. Third, 
there is considerable uncertainty in model estimates, particu-
larly regarding the clinical benefit of pre-emptive therapy in 
ART-experienced patients. Fourth, we used local CD4 testing 
practices in Botswana to inform these estimates. Alternative test-
ing practices, such as testing only ART-experienced patients 
who have treatment failure based on HIV viral load testing or 
who are newly engaging in care following default, may result 
in greater cost-effectiveness of reflex CrAg testing.
In summary, nationwide CrAg screening in patients with 
advanced HIV disease with a CD4 count of 101–200 cells/µL in 
Botswana is estimated to have a modest impact (48 deaths 
avoided annually) for a modest additional cost to the over-
all HIV/AIDS care and treatment program ($116,000), with a 
relatively low cost per DALY saved ($114 base case). With less 
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coverage of pre-emptive treatment for CrAg positive patients, 
the cost per DALY saved, compared to no screening, is esti-
mated at about $350. Overall, expanding screening to this 
higher CD4 count population would be estimated to require 
about 33,000 additional CrAg tests annually, with an estimated 
cost of about $156,000. The decision of whether or not to adopt 
CrAg screening in national HIV advanced disease guidelines 
among patients with higher CD4 counts (101–200 cells/µL) 
will rely on the availability of these additional resources and 
competing health system priorities.
Data availability
Underlying Data
Open Source Framework: Cryptococcal antigen screening in 
Botswana, CD4 101–200. https://doi.org/10.17605/OSF.IO/
GN98V12.
This project contains the following underlying data:
-    CD4 100–200 full model data.xlsx
Extended data
Open Source Framework: Cryptococcal antigen screening in 
Botswana, CD4 101–200. https://doi.org/10.17605/OSF.IO/
GN98V12.
This project contains the following extended data:
-    Figures S1 (flowchart of screening module) and S2 (flow-
chart of treatment module)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Elizabeth Nalintya  
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The study title is short and smart and gives a glimpse into what the paper is about. The study is 
well introduced however I would reorganize the paragraphs to get a better flow, that is: 
The first sentence of paragraph two can be moved to the beginning of the introduction to draw 
the picture on how big the HIV problem is in Botswana upfront and then talk about the rationale 
after. I would merge and reorganize the first two paragraphs. 
 
In the methods section, a great deal of work has gone into explaining how the different estimates 
were arrived at and what type of data was used to arrive at the estimates. This however blurs the 
description of the actual modeling. It would be beneficial to the reader to get a quick snap short of 
the final model (could be in a summarized figure placed within the text explaining the methods) 
This is especially because the figure S1 is very busy and can get confusing, the reader needs to 
understand what the final model is before trying to understand the smaller details of how the 
model was arrived at. 
 
The screening model clearly talks about the estimates included and how they are arrived at. The 
viral load(VL) test is used as the proxy for ART experience, it would be good to know if all these VL 
tests are done after 6 months of ART or at what time point this is done. Pragmatically with all 
logistical challenges in resource limited settings, a recommendation to do a six month viral load 
will mean the viral load was done at about  month eight or nine after ART start. Wondering if this 
choice of defining ART experience could have lumped many ART experience persons as non 
experienced.  
 
Page 3, the last paragraph talks about the assumptions for those who did not receive CrAG 
screening, however its not clear where these estimates are derived from. Is this lab data or data 
from the prospective cohort. Also it seems to belong under the next subheading and yet has been 
placed under the screening model. 
 
The base model, the cost analysis and the sensitivity analysis are presented well and in detail and 
are supplemented by the tables giving a clear picture of what was being done. The discussion of 
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study findings is comprehensive and puts them in context and the conclusions have been derived 
systematically from the data presented.
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